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Abstract
Background: Hereditary gelsolin (AGel) amyloidosis is an autosomal dominantly inherited systemic amyloidosis that
manifests with the characteristic triad of progressive ophthalmological, neurological and dermatological signs and
symptoms. The National Finnish Gelsolin Amyloidosis Registry (FIN-GAR) was founded in 2013 to collect clinical data
on patients with AGel amyloidosis, including altogether approximately one third of the Finnish patients. We aim to
deepen knowledge on the disease burden and life span of the patients using data from the updated FIN-GAR
registry. We sent an updated questionnaire concerning the symptoms and signs, symptomatic treatments and
subjective perception on disease progression to 240 members of the Finnish Amyloidosis Association (SAMY). We
analyzed the lifespan of 478 patients using the relative survival (RS) framework.
Results: The updated FIN-GAR registry includes 261 patients. Symptoms and signs corresponding to the classical
triad of ophthalmological (dry eyes in 93%; corneal lattice amyloidosis in 89%), neurological (numbness, tingling
and other paresthesias in 75%; facial paresis in 67%), and dermatological (drooping eyelids in 86%; cutis laxa in
84%) manifestations were highly prevalent. Cardiac arrhythmias were reported by 15% of the patients and 5% had a
cardiac pacemaker installed. Proteinuria was reported by 13% and renal failure by 5% of the patients. A total of 65%
of the patients had undergone a skin or soft tissue surgery, 26% carpal tunnel surgery and 24% at least unilateral
cataract surgery. As regards life span, relative survival estimates exceeded 1 for males and females until the age
group of 70–74 years, for which it was 0.96.
Conclusions: AGel amyloidosis causes a wide variety of ophthalmological, neurological, cutaneous, and oral
symptoms that together with repeated surgeries cause a clinically significant disease burden. Severe renal and
cardiac manifestations are rare as compared to other systemic amyloidoses, explaining in part the finding that AGel
amyloidosis does not shorten the life span of the patients at least for the first 75 years.
Keywords: Gelsolin, Amyloidosis, AGel, Hereditary amyloidosis, Meretoja syndrome, Natural history, Lifespan,
Relative survival
Background
Hereditary gelsolin amyloidosis (AGel amyloidosis;
OMIM#105120), also called Meretoja syndrome according
to the Finnish ophthalmologist Jouko Meretoja who first
described it in 1969 [1], is an autosomal dominantly inher-
ited systemic amyloidosis. The most common clinical
signs in patients with AGel amyloidosis are progressive
ophthalmological (corneal lattice amyloidosis), neuro-
logical (cranial and peripheral neuropathy), and dermato-
logical (cutis laxa) signs, manifesting typically in their
forties or fifties [2, 3]. Also other internal organ, especially
renal [4–6], and cardiac [4, 5, 7–10], manifestations have
been reported. The symptoms of AGel amyloidosis are
suggested to be based on the deposition of gelsolin-based
amyloid (AGel) fibrils and pre-amyloid oligomers, origin-
ating from misfolded gelsolin fragments and accumulating
in multiple organs and tissues [2, 11]. So far it is not
known why the manifestations of the disease vary remark-
ably between the patients [2].
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Gelsolin is a calcium-activated, actin-modulating protein
that has a role in multiple biological processes, and is
present both in cytosolic and secretory forms in most cells
[12–14]. AGel amyloidosis is caused either by the point
mutation c.640G >A in the gelsolin gene on chromosome
9 at q33.2 [15, 16] or, less frequently, by the mutation
c.640G >T at the same locus [2, 8, 17–23]. Two novel gel-
solin gene variants (c.633C >A, c.580G >A) causing renal
amyloidosis have recently been reported in the US [24, 25].
The penetrance of the c.640G >A pathogenic variant is
100%. The prevalence of this mutation in Finland seems to
be higher than anywhere else but individual patients and
kindreds have also been reported in several other countries
[2]. Estimates of the number of patients in Finland vary
from 600 to 1000 [2, 3].
Meretoja himself began to chart the natural course of
AGel amyloidosis [1]. Since his time, the prevalence and
progression of its various signs and symptoms have been
reported in several smaller cohorts and case reports.
Our research group founded the National Finnish Gelso-
lin Amyloidosis Registry (FIN-GAR) in 2013 in order to
increase the understanding on the natural course of this
rare amyloidosis. Altogether 227 patients (211 living, 16
deceased) were entered in the registry in 2013–2014, es-
timated to cover approximately one third of the Finnish
patients [3]. Our study showed that the patients become
symptomatic at the mean age of 39 years and that oph-
thalmologic symptoms were the first to appear. The high
prevalence of the characteristic triad of ocular, neuro-
logical and cutaneous symptoms was demonstrated [3].
However, open questions remained concerning the less
well known of the anticipated symptoms, the symptom-
atic treatments, and disease progression.
Meretoja suggested in 1973 that the mortality of AGel
amyloidosis patients might be somewhat increased [26].
In a previous study by our research group, however,
based on death certificates of 231 patients who died in
1980–2014, the lifespan was shown to be comparable to
that of the general Finnish population [27]. That study
was based exclusively on data from deceased patients,
which might have caused bias, and thus the result must
be confirmed in a representative patient group including
both the living and the deceased patients.
In our present study (FIN-GAR phase II), the data in
the FIN-GAR patient registry were updated and 29 new
patients were entered into the registry, increasing the
total number of the patients to 261. More comprehen-
sive overview of their various signs and symptoms,
symptomatic treatments, and disease progression was
obtained by introducing a more detailed survey. In
addition, our study increases knowledge on the survival
of AGel amyloidosis patients. We compared the lifespan
of 478 living and deceased patients to that of the general
Finnish population, utilizing relative survival analysis. To
our knowledge, this is the most comprehensive study on
the natural history of AGel amyloidosis.
Results
The FIN-GAR phase II questionnaire was returned by
129 patients, which corresponds to 54% of SAMY mem-
bers. Of these 129 patients, 100 (47% of the surviving
patients) had taken part in FIN-GAR phase I in 2013–
2014, and 29 patients were new. As a result, FIN-GAR
phase II registry includes 261 patients, of whom 183
(70%) are females and 78 (30%) males. Their mean age is
62.7 years (range, 26 to 85). Genetic testing to confirm
the AGel c.640G > A variant had been done for 138
(53%) patients, one of whom is a homozygote. The mean
follow-up time for the patients included in both phases
was 4.9 years (range, 4.1–5.6). Baseline information re-
garding patients in the FIN-GAR phase II registry is pre-
sented in Table 1. The symptoms, their frequency and
the median age at onset are presented in Table 2, and
the percentage of patients receiving specific symptomatic
treatments is presented in Table 3.
Ophthalmological manifestations
Corneal lattice amyloidosis (previously incorrectly called
lattice corneal dystrophy, type II) is the first ophthalmo-
logical sign to appear (median age at diagnosis, 41 years)
and 231 (89%) patients reported to suffer from it. Dry
eyes is an even more common problem, affecting 242
(93%) patients (median age, 45 years). Photophobia and
tearing were inquired separately only in the phase II
questionnaire and the results are based on those 129 pa-
tients. Photophobia was reported by 101 (78%) patients
(median age, 49 years) and tearing by 34 (26%) patients
(median age, 56 years). Cataract was reported by 123
(47%) patients (median age, 62 years) and glaucoma by
60 (23%) patients (median age, 61 years). Of patients in-
cluded in phase I and II, 95 (74%) told that their oph-
thalmological symptoms had progressed in the past 5
years.
Table 1 Baseline information on the patients with AGel
amyloidosis in the FIN-GAR phase II registry
Number of patients 261
Gender distribution 183 (70%) female, 78 (30%)
male
Mean age of the patients 62.7 years (range 26.3–85.8
years)
Median age of the patients 64.7 years (interquartile range
54.9–71.2 years)
Mean age at diagnosis of AGel
amyloidosis
40.7 years (range
10.4–68.7 years)
Genetic testing done 138 (53%)
Follow-up time after FIN-GAR phase I 4.9 years (range 4.1–5.6 years)
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Artificial tears were used by 121, approximately one
half (46%) of the patients, and 197 (75%) visited their
ophthalmologist regularly. At least unilateral cataract
surgery was performed for 62 (24%) patients. The me-
dian age at the time of the first cataract surgery was 67
years. The cumulative frequency of selected surgeries is
presented in Fig. 1.
Cutaneous and soft tissue manifestations
The most prevalent cutaneous symptom was drooping
eyelids, caused by cutis laxa and aggravated by facial
nerve paresis, reported by 225 (86%) patients (median
age at onset, 50 years). Cutis laxa, abnormal general
loosening of the skin, was reported by 219 (84%) pa-
tients (median age, 50 years), dry skin by 206 (79%)
patients (median age, 40 years), and itchiness of the
skin by 85 (33%) patients (median age, 49 years). Con-
sequently, 110 (85%) patients used regularly moistur-
izing skin creams. The skin appears to be vulnerable
to injury: 180 (69%) patients (median age, 39 years)
suffered from tendency to bruising and 82 (64%) pa-
tients (median age, 34 years) reported getting wounds
easily.
Manifestations of AGel amyloidosis may also include
pathological changes in soft tissues other than the skin.
Varicose veins were reported by 39 (30%) patients (me-
dian age at onset, 36 years), haemorrhoids by 38 (29%)
patients (median age, 42 years), and hernias of different
types by 30 (11%) patients (median age, 49 years),
whereas 21 (8%) patients reported at least one prolapse
of any type (median age, 41 years). Of patients who took
part in both phases, 95 (72%) had the perception that
their skin and other soft tissue-related symptoms had
progressed during the follow-up.
Skin or other soft tissue surgeries had been performed
in 261 (65%) patients. On average, patients had gone
through 2.4 such surgeries (range, 1–16; Fig. 2) and the
median age at the time of the first surgery in 129 pa-
tients was 53 years (interquartile range, 48–72 years).
Neurological manifestations
The most prevalent neurological symptoms were numb-
ness, tingling and other paresthesias, reported by 195
(75%) patients (median age at onset, 56 years). Facial
paresis in 176 (67%) patients become symptomatic at the
median age of 50 years. Other frequent manifestations
were myokymias (54%; median age, 48 years), carpal tun-
nel syndrome (43%, 50 years), balance impairment (39%,
64 years) and dysarthria (31%, 61 years). Patients with
dysarthria reported especially difficulty in articulating
clearly outdoors in cold weather. Approximately half
(53%) of the patients participating in both phases stated
that their neurological symptoms had progressed during
the follow-up. Of 111 (43%) patients with a carpal tunnel
syndrome diagnosed, 68 (61%) underwent surgery at a
median age of 50 years (Fig. 1).
Cardiovascular manifestations
In the updated questionnaire, we asked spesifically about
cardiac arrhythmias other than atrial fibrillation, whereas
in the previous questionnaire there was only a general
question regarding arrhythmias. Of patients who
returned the updated questionnaire, 20 (15%) reported
cardiac arrhythmias and 6 (5%) atrial fibrillation, another
6 (5%) suffered from cardiac failure, and 12 (9%) had an
ischaemic heart disease. Cardiomyopathy was reported
by 13 (5%) patients. Pacemaker was installed for 12 pa-
tients (5%), and 8 (6%) patients reported a history of any
kind of cardiac surgery of which 4 were bypass surgeries
or angioplastias. The majority (61%) of the patients were
not aware of any cardiovascular signs or symptoms, ex-
cluding hypertension and hypercholesterolemia. How-
ever, 12 (9%) patients reported that they had
experienced progression in their cardiac symptoms dur-
ing the follow-up.
Renal manifestations
Proteinuria had been detected in 35 (13%) patients (me-
dian age at onset, 54 years). Renal failure was reported
by 14 (5%) patients and two patients (2%) used medica-
tions for renal disease. Moreover, 3 (1%) patients re-
ceived or had previously received dialysis treatment, and
kidney transplantation had been performed to 5 (2%) pa-
tients. Conversely, 111 (86%) patients who returned the
updated questionnaire reported no kidney-related signs
or symptoms, and only 6 (5%) had the perception that
their renal symptoms had progressed during the follow-
up.
Other manifestations
Regarding oral health, 111 patients (43%) reported dry
mouth, 55 (43%) caries, and 25 (19%) gingivitis. One fifth
of the patients (19%) reported no oral health issues, but
Table 3 Patients with AGel amyloidosis in the FIN-GAR phase II
registry with specific symptomatic treatments
Symptomatic treatment and follow Frequency (%) n Total
Moisturizing skin creams 85 110 129
Skin and soft tissue surgery 65 170 261
Artificial tears 46 121 261
Carpal tunnel syndrome surgery 26 68 261
Cataract surgery 24 62 261
Hearing aid or cochlear implant 9 23 261
Pacemaker 5 12 261
Kidney transplantation 2 5 261
Dialysis 1 3 261
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Fig. 1 The cumulative frequency of selected surgeries in 261 patients with AGel amyloidosis in the FIN-GAR phase II registry. a: Skin or other soft
tissue surgeries (n = 170, 65%). b: Cataract surgeries (n = 62, 24%). c: Carpal tunnel syndrome surgeries (n = 68, 26%)
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approximately one third (35%) reported worsening oral
health.
Patients also reported other symptoms possibly linked
to AGel amyloidosis based on previous studies. Impaired
hearing was reported by 112 (43%) patients and 23 (9%)
patients had a hearing aid or cochlear implant. Oedema
as an unspecific symptom, possibly in some patients re-
lated to renal problems, was reported by 72 (28%) pa-
tients. Sleep apnoea was reported by 15 (6%),
hypothyroidism by 25 (10%), different kinds of pain by
99 (38%), cancer by 19 (15%), and depression by 17
(13%) patients.
Retirement and relative survival
Of the male and female patients, 42 (54%) and 99 (54%)
had retired at mean age of 57.9 and 59.1 years,
respectively.
We compared the lifespan of the patients with that of
the general Finnish population using the relative survival
framework (Table 4, Fig. 3). Relative survival was com-
parable to that of the general population at least until
the age of 75 years: in the age group of 70–74 years old,
i.e. after 30 to 40 years after the first symptoms, the rela-
tive survival was 0.96 for both male and female patients.
After the age of 75, less than 100 patients remained in
the analysis and the observed survival was thereafter
lower than the expected survival for both genders.
Discussion
Our registry study, FIN-GAR phase II, included 261
Finnish AGel amyloidosis patients of whom 29 were
new. The registry is estimated to represent 25–40% of
Finnish AGel patients, which we consider to be a
reasonably large sample of all patients suffering from
this rare disease. Our study describes the typical course
of the disease and shows that symptoms and signs corre-
sponding to the classical triad of ophthalmological (dry
eyes in 93%; corneal lattice amyloidosis in 89%), neuro-
logic (numbness, tingling and other paresthesias in 75%;
facial paresis in 67%), and cutaneous (drooping eyelids
in 86%; cutis laxa in 84%) manifestations are highly
prevalent. Our study increases knowledge on the diver-
sity of symptoms by showing that, in addition to previ-
ously known ones, a significant proportion of patients
suffer from symptoms such as photophobia and a hear-
ing deficit.
The prevalence of various ophthalmological manifesta-
tions was shown to be high in AGel amyloidosis patients
but comparison data on prevalence of dry eyes, photo-
phobia and tearing in the general population is not avail-
able. In a population based survey on the prevalence of
major eye diseases in Finland [28], partly based on self-
reported data similarly to this study, the prevalence of
cataract and glaucoma for persons aged 30 years and
older was reported to be 10 and 5%, and for persons
aged 65 years and older 34 and 13%, respectively. In
FIN-GAR registry patients with median age of 62.7 years
the prevalence of cataract was 47% and that of glaucoma
23%. Cataract and glaucoma have been associated to
AGel amyloidosis [4, 6, 29–35], but this high prevalence
in patients was new information received through this
study.
Understanding cardiac manifestations in AGel amyl-
oidosis has been mainly based on smaller patient series
and case reports that have reported conduction defects,
such as atrioventricular blocks, sinus bradycardia, and
Fig. 2 Number of skin surgeries in 89 patients with AGel amyloidosis in the FIN-GAR phase II registry, including eyelid and other facial surgeries,
hernia and prolapse surgeries, and varicose vein surgeries
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sick sinus syndrome [4, 7–10]. In a series of 30 patients,
signs of amyloid cardiopathy were rare both at clinical
and in radiologic, echocardiographic and electrocardio-
graphic examinations in middle-aged patients [36]. Val-
vulopathies have been observed in occasional patients [5,
7, 8]. Finally, only one patient with heart transplantation
has been reported [37]. Our study confirms the previous
assumption that severe clinical cardiac manifestations in
AGel amyloidosis are rather rare, especially when com-
pared with other systemic amyloidoses, such as AL and
transthyretin (ATTR) amyloidosis. This is interesting,
knowing that all investigated patients in our recent aut-
opsy study of 25 patients had amyloid deposits in both
myocardium and in cardiac blood vessels [38]. However,
the study revealed that 5% of the patients have a pace-
maker. It is more than in the general population: in year
2013 in Finland a total of 1020 new pacemakers per
million inhabitants were installed [39], and the total
prevalence of pacemakers in the population of the
Helsinki University Hospital area is approximately 1%
[40]. Relatively low frequency of severe cardiac manifes-
tations likely contributes to the reasonably normal life
span of AGel patients. However, notable individual vari-
ation in the phenotype means that, in rare cases, cardiac
manifestations can be significant.
Similarly, the assumption has been that renal manifest-
ation of AGel amyloidosis are rather rare and mild in
heterozygous patients [4–6]. However, some patients
have developed even a nephrotic syndrome [26, 35, 41],
requiring dialysis or kidney transplantation. On the
other hand, homozygous patients have severe renal man-
ifestations and they may suffer from nephrotic syndrome
already in their early twenties, progressing to renal fail-
ure, dialysis treatment, and death [26, 42, 43]. The two
Table 4 Relative survival for 188 male and 290 female patients with AGel amyloidosis in the FIN-GAR phase II registry and a
previous study on survival [27]
Age group n in the beginning Observed survival Expected survival Cumulative relative survival
Male
30–34 188 0.9893 0.9777 1.0119
35–39 185 0.9893 0.9577 1.0330
40–44 183 0.9839 0.9360 1.0511
45–49 180 0.9674 0.9065 1.0671
50–54 174 0.9448 0.8669 1.0899
55–59 165 0.8800 0.8136 1.0817
60–64 145 0.8172 0.7415 1.1021
65–69 125 0.7073 0.6468 1.0936
70–74 97 0.5085 0.5300 0.9594
75–79 62 0.3221 0.3927 0.8200
80–84 36 0.0552 0.2550 0.2165
85–89 5 0.0000 0.1274 0.0000
Female
30–34 290 1.0000 0.9907 1.0094
35–39 287 0.9965 0.9820 1.0147
40–44 284 0.9965 0.9728 1.0244
45–49 280 0.9929 0.9610 1.0332
50–54 267 0.9813 0.9448 1.0387
55–59 246 0.9688 0.9220 1.0507
60–64 222 0.9459 0.8883 1.0648
65–69 195 0.8370 0.8386 0.9982
70–74 149 0.7339 0.7641 0.9605
75–79 110 0.4703 0.6494 0.7241
80–84 59 0.1513 0.4863 0.3112
85–89 17 0.0504 0.2809 0.1796
90–94 5 0.0101 0.0994 0.1015
95–99 1 0.0000 0.0182 0.0000
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recently reported gelsolin gene variants c.580G > A and
c.633C > A seem to exclusively cause renal amyloidosis
[24, 25]. Before the FIN-GAR registry, the true fre-
quency of renal signs and symptoms was unknown. Our
study confirms that severe renal manifestations are rare
in AGel amyloidosis.
Hyposalivation and altered salivary composition have
been suggested to increase the risk of caries and oral
candidiasis in patients with AGel amyloidosis [44]. In
our study, over 40% of the patients reported that they
suffered from a dry mouth, and equally many from a
tendency to caries, indicating that oral health care is an
important part of symptomatic treatment of the patients.
The high frequency of skin and soft tissue surgeries is
also an interesting observation. As many as 65% of the
patients had been operated on at least once, and re-
peated skin or soft tissue surgeries had been completed
for 45% of them. Tissue laxity was not limited to the
skin, because patients reported also varicose veins, hae-
morrhoids, hernias, and prolapses, frequently requiring
Fig. 3 Relative survival of a) males and b) females with AGel amyloidosis in the FIN-GAR phase II registry and a previous study on survival. RS =
relative survival [27]
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surgical treatment. However, the prevalence of varicose
veins does not seem to be higher than in the general
population [45]. An earlier study suggested that repeated
plastic surgery is needed because its effects, although
satisfactory, are only short-term [46]. Facial surgeries are
likely due to the progressive changes in the structure of
the skin. An increasing amount of amyloid in the skin is
found with advancing age, and amyloid spreads even to
the deeper dermis and subcutaneous adipose tissue [47].
In addition, the characteristic facial nerve palsy that be-
gins from the frontal branch of the nerve hastens the
visible facial changes. In a series of 35 operated patients,
none had normal function of the frontal branch of the
facial nerve, and weakness in the buccal branch was seen
in 40% [46].
The patients (42 males and 99 females) had retired
between 1968 and 2019. Statistical data on the age of re-
tirement in Finland is available only for years 1996–
2018. During that period, the mean age of retirement
varied from 56.6 to 60.9 years for males and from 57.8 to
60.7 years for females [48]. Males and females with AGel
amyloidosis retired at the mean age of 57.9 years and
59.1 years, respectively. AGel amyloidosis does not seem
to have a major influence on the age of retirement.
The lifespan of the patients was modeled using the
relative survival framework, and the result of a previous
study [27] was confirmed: the lifespan was not shorter
than that of general Finnish population. The explanation
why the observed survival of the patients was lower than
the expected one in the oldest age groups is likely the
small number of patients in these cohorts, causing bias.
AGel amyloidosis seems to be an exception among other
systemic amyloidosis in respect to the life span. Of other
hereditary systemic amyloidoses, ATTR amyloidosis
leads to death on average in 10 years after the disease
onset [49], cystatine (ACys) amyloidosis before the age
of 40 years [50], fibrinogen (AFib) amyloidosis within a
median of 15.2 years after disease manifestation [51],
and in lysozyme (ALys) amyloidosis the survival varies
remarkably from 1 to 20 years after disease onset [52].
Especially the relative rarity of severe cardiac and renal
manifestations likely contribute to this finding. The pre-
liminary finding of our previous study [27] that the
frequency of cancer as a cause of death in patients with
AGel amyloidosis is lower than in the general population
may also have an influence on their survival. It is inter-
esting that although the disease burden is significant, the
lifespan is comparable to that of the general population,
at least until the age of 75 years, and the patients do not
retire earlier than the general population.
Our study has several limitations. Of the surviving
patients in the FIN-GAR phase I registry, 47% responded
in the phase II questionnaire, and the results are partly
based on the information reported already in our
previous study [3]. The data were self-reported and col-
lected through a patient survey, and complemented by
telephone interviews in the phase I study, and not all the
reported signs and symptoms were verified by a phys-
ician, which may artificially increase their prevalence.
However, we consider it unlikely that patients would
report certain signs like cataract or glaucoma without
having a diagnoses made by an ophthalmologist. As the
symptoms begin gradually, over many years, and many
patients have a spectrum of different symptoms, memor-
izing the exact starting point of each symptom is subject
to recall error. For this reason, the given years of onset
must be taken as rough estimates in most cases.
Secondly, patients were recruited through a disease-
specific patient organisation. Patients registered as mem-
bers might differ from those who declined such
activities, as might patients who returned and did not
return the phase II questionnaire either because they
had less health problems or were more debilitated. Like-
wise, the gender distribution in our study was uneven,
which may be due to the fact that female patients in
general are more likely to answer questionnaires. On the
other hand, our data represent an estimated 25–40% of
all Finnish AGel amyloidosis patients, which provides
reasonable assurance of representativeness.
Conclusions
We have presented here the most up to date and com-
prehensive cross-sectional study on AGel amyloidosis.
The results reported in FIN-GAR phase I study were
confirmed and data on several new symptoms and signs,
use of symptomatic treatment, and performed surgeries
add to the knowledge on the course and the burden of
AGel amyloidosis. Our study emphasizes the clinical
significance of the classical triad of ophthalmologic,
neurologic and cutaneuous symptoms and signs, and
confirms the earlier hypothesis that cardiac and renal
manifestations are not very common in this amyloidosis.
However, for yet unknown reasons and possibly related
to the variability in the phenotype, patients rarely may
develop severe cardiac or renal amyloidosis, leading to
organ transplantation or even death.
Methods
Between September 2013 and June 2014 altogether 227
patients were entered into the FIN-GAR registry, and
five more patients were added later in 2014–2017. In
phase I, we interviewed most of the patients (87%) on
telephone to complement the data given in the question-
naire. Full update (phase II) commenced in September
2018, 5 years after founding the registry.
An updated questionnaire, including a larger scale of
known and anticipated symptoms and signs of AGel
amyloidosis and their time of onset, was created.
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Because new patients were recruited, baseline informa-
tion regarding primary symptoms, details of diagnosis
and family history were inquired, similarly to the phase I
questionnaire. In addition, the new questionnaire
inqueried about possible symptomatic treatments that
were either self-administered or provided by the health
care system. Finally, the patients were asked about their
subjective perception of the progression of their symp-
toms in different organs since the previous question-
naire, approximately 5 years earlier.
The Finnish Amyloidosis Association (SAMY; Suomen
amyloidoosiyhdistys ry), sent the questionnaire to their
240 members. The pathognomonic clinical manifesta-
tions of AGel amyloidosis consist of the triad of corneal
lattice amyloidosis, peripheral facial paresis and cutis
laxa. This triad is not seen in any other known disorder
[2], and for this reason, genetic testing is not required
for diagnosis, especially if there are known cases of AGel
amyloidosis in the family. Data received from patients
who had participated in the FIN-GAR phase I were
updated in the registry, and new patients, not previously
entered in the registry, were included.
Because several new questions were added to the FIN-
GAR phase II questionnaire, part of the endpoints could
be analysed only for those 129 patients who returned
that questionnaire. The analysed patient group is indi-
cated in Table 2 by each symptom and sign. Regarding
the endpoints for which data were available also from
the FIN-GAR phase I study, the registry data were up-
dated and the analyses were done for the complete regis-
try of 261 patients. The patient inclusion process is
presented in Fig. 4. The frequencies and the median age
at the onset of the symptoms/signs were calculated. Dis-
tributions of continuous variables were analysed and
tested for normality. The cumulative frequency of se-
lected surgeries was plotted according to the age of the
patient at the time of the surgery. These figures were
constructed based on data from the patients who had
the symptom of interest. IBM SPSS version 25 (SPSS,
Inc., an IBM company, New York, NY) was used for the
analyses.
The lifespan of AGel amyloidosis patients was calcu-
lated based on survival data of 478 living and deceased
patients. First, we extracted survival data from 272 death
certificates that we collected for a previous study [27].
Then, survival data of 208 living patients was added
from the FIN-GAR phase I patient registry; late patients
of FIN-GAR phase I registry were already included in
the data extracted from the death certificates. After data
quality control we removed two subjects from the data
set prior to the analysis. The lifespan was analysed using
the relative survival framework, based on Ederer II esti-
mator [53]. Relative survival is defined as the ratio of the
all-cause survival of the patients to the all-cause survival
that would be expected [54]. If relative survival is 1, the
patient group survives equally in comparison to the
background population, in this case general age, gender
and calendar year matched Finnish population. If the
disease of interest is rare, any difference in survival can
be assumed to be due to that disease. Thus, the relative
survival framework does not need information about the
cause of death. Information concerning the general
Finnish population was obtained from Statistics Finland.
For the purpose of running the analysis, disease onset
was set to the age of 30 years, and relative survival was
estimated in five year time intervals using Stata (version
13, StataCorp, College Station, TX).
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